Overview

A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis

Status:
Recruiting

Trial end date:
2028-09-01

Target enrollment:

Participant gender:

Summary

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3

Phase:

Phase 3

Details

Lead Sponsor:

Inventiva Pharma